Latest Revenue Growth News

Little Green Pharma reported a robust 40% revenue increase for FY25, driven by strong European sales and the strategic acquisition of Health House. The company also advanced clinical research and secured new therapy funding, positioning itself for continued growth.

Lucapa Diamond Company Limited reported a robust Q1 2025 with a 74% increase in diamond grade at Lulo and a 36% revenue rise, while advancing its stake in the Lulo JV to 51%. Exploration at Merlin in Australia revealed significant new targets, setting the stage for further growth.

Locate Technologies Limited reported flat group revenue for Q3 FY25, with Locate2u growing 10% while Zoom2u declined 11%. The company continues to embed AI as a strategic growth and cost optimization tool.

Zoom2u Technologies reports steady group revenue with Locate2u growing 10%, supported by AI initiatives that cut staff costs and a $0.5 million capital raise.

RooLife Group Ltd (RLG) has inked exclusive decade-long agreements with three Chinese companies to market and distribute branded solar energy systems worldwide, marking a strategic expansion into the renewable energy sector.

Cluey’s Q3 FY25 results reveal a strong 24% surge in new student enrolments and a narrowing underlying EBITDA loss, signaling a pivotal step toward profitability and renewed revenue growth.

Beonic Limited reported a 6.5% increase in annual recurring revenue to $17.8 million and a significant gross margin improvement to 75.5%, driven by new global contracts and disciplined cost management. The company targets cash flow breakeven in Q4 FY25 and an EBITDA margin of up to 15%.

Cluey Ltd reported a 24% surge in new student enrolments in Q3 FY25 alongside a 46% reduction in cash burn, signaling improved operational efficiency and a clearer path to profitability.

Microba Life Sciences reported robust Q3 FY25 growth in its microbiome diagnostic tests, led by MetaXplore and MetaPanel, while advancing its therapeutics pipeline and projecting strong full-year revenue growth.

Althea Group Holdings reported $5.02 million in Q3 FY25 receipts, driven by strong growth at Peak Canada and the launch of Peak USA, while its pharmaceutical cannabis division faces steep revenue declines prompting strategic review.

Orthocell has secured Health Canada approval for its nerve repair product Remplir™, adding the US$75 million Canadian market and expanding its total addressable market to US$1.8 billion. The company plans to appoint local distributors and expects first sales in H2 2025.

Gratifii Limited reported a record quarterly cash receipt surge of 111% year-on-year, driven by key contract wins and successful platform migration despite cyclone disruptions. The company advances its post-merger integration and eyes an $84m revenue run rate in FY26.